<SEC-DOCUMENT>0001193125-23-267001.txt : 20231031
<SEC-HEADER>0001193125-23-267001.hdr.sgml : 20231031
<ACCEPTANCE-DATETIME>20231031125156
ACCESSION NUMBER:		0001193125-23-267001
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20231031
FILED AS OF DATE:		20231031
DATE AS OF CHANGE:		20231031

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Theratechnologies Inc.
		CENTRAL INDEX KEY:			0001512717
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			A8
		FISCAL YEAR END:			1130

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35203
		FILM NUMBER:		231363454

	BUSINESS ADDRESS:	
		STREET 1:		2015 PEEL STREET
		STREET 2:		5TH FLOOR
		CITY:			MONTREAL
		STATE:			A8
		ZIP:			H3A 1T8
		BUSINESS PHONE:		514-336-7800

	MAIL ADDRESS:	
		STREET 1:		2015 PEEL STREET
		STREET 2:		5TH FLOOR
		CITY:			MONTREAL
		STATE:			A8
		ZIP:			H3A 1T8
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d559945d6k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML><HEAD>
<TITLE>6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C.&nbsp;20549 </B></P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">6-K</FONT> </B></P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Report of
Foreign Private Issuer </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to Rule <FONT STYLE="white-space:nowrap">13a-16</FONT> or
<FONT STYLE="white-space:nowrap">15d-16</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>under the Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>October&nbsp;31, 2023 </B></P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number <FONT STYLE="white-space:nowrap">001-35203</FONT> </B></P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>THERATECHNOLOGIES INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of registrant&#146;s name into English) </B></P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2015 Peel
Street, Suite 1100 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Montr&eacute;al, Qu&eacute;bec, Canada </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>H3A 1T8 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Address of
principal executive offices) </B></P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant files or will file annual reports under cover of Form
<FONT STYLE="white-space:nowrap">20-F</FONT> or Form <FONT STYLE="white-space:nowrap">40-F:</FONT> </P> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form
<FONT STYLE="white-space:nowrap">20-F&#8194;&#9744;&#8195;&#8195;&#8195;Form</FONT> <FONT STYLE="white-space:nowrap">40-F&#8194;&#9746;</FONT> </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form <FONT STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by
Regulation <FONT STYLE="white-space:nowrap">S-T</FONT> Rule 101(b)(1): </P> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Yes&#8194;&#9744;&#8195;&#8195;&#8195;No&#8194;&#9746; </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Note: Regulation <FONT STYLE="white-space:nowrap">S-T</FONT> Rule 101(b)(1) only permits the submission in paper of a Form <FONT
STYLE="white-space:nowrap">6-K</FONT> if submitted solely to provide an attached annual report to security holders. </P> <P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Indicate by check
mark if the registrant is submitting the Form <FONT STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by Regulation <FONT STYLE="white-space:nowrap">S-T</FONT> Rule 101(b)(7): </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Yes&#8194;&#9744;&#8195;&#8195;&#8195;No&#8194;&#9746; </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Note: Regulation <FONT STYLE="white-space:nowrap">S-T</FONT> Rule 101(b)(7) only permits the submission in paper of a Form <FONT
STYLE="white-space:nowrap">6-K</FONT> if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or
legally organized (the registrant&#146;s &#147;home country&#148;), or under the rules of the home country exchange on which the registrant&#146;s securities are traded, as long as the report or other document is not a press release, is not required
to be and has not been distributed to the registrant&#146;s security holders, and, if discussing a material event, has already been the subject of a Form <FONT STYLE="white-space:nowrap">6-K</FONT> submission or other Commission filing on EDGAR.
</P> <P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the
information to the Commission pursuant to Rule <FONT STYLE="white-space:nowrap">12g3-2(b)</FONT> under the Securities Exchange Act of 1934. </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Yes&#8194;&#9744;&#8195;&#8195;&#8195;No&#8194;&#9746; </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If &#147;Yes&#148; is marked, indicate below the file number assigned to the registrant in connection with Rule
<FONT STYLE="white-space:nowrap">12g3-2(b):</FONT> <FONT STYLE="white-space:nowrap">82-______________.</FONT> </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>THERATECHNOLOGIES INC. </U></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="93%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Exhibit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP ALIGN="center">99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release Dated October&nbsp;31, 2023</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">THERATECHNOLOGIES INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">/s/ Jocelyn Lafond</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Jocelyn Lafond</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">General Counsel and Corporate Secretary</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: October&nbsp;31, 2023 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d559945dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g559945g1031190144799.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Theratechnologies Announces Closing of US$25 Million Public Offering of </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Common Shares and Concurrent Private Placement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>This news release constitutes a &#147;designated news release&#148; for the purposes of the Company&#146;s prospectus supplement dated
December&nbsp;16, 2021 to its short form base shelf prospectus dated December&nbsp;14, 2021. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Montreal, Quebec, October</B><B></B><B>&nbsp;31, 2023
</B>&#150; Theratechnologies Inc. (&#147;Theratechnologies&#148; or the &#147;Company&#148;) (Nasdaq: THTX; TSX: TH), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has
closed its previously announced public offering (the &#147;Public Offering&#148;) of 12,500,000 common shares of the Company (the &#147;Common Shares&#148;) at a public offering price of US$1.00 per Common Share (the &#147;Offering Price&#148;). The
gross proceeds of the Public Offering are US$12,500,000, before deducting the underwriting discounts and commissions and other estimated offering expenses. Pursuant to the underwriting agreement dated October&nbsp;25, 2023, the Company has also
granted the underwriter a <FONT STYLE="white-space:nowrap">30-day</FONT> option (the &#147;Option&#148;) to purchase up to 1,875,000 Common Shares at the Offering Price, less underwriting discounts and commissions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cantor Fitzgerald&nbsp;&amp; Co. acted as sole bookrunner for the Public Offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the Public Offering, the Company has also closed its concurrent private placement with Investissement Qu&eacute;bec (the &#147;Concurrent
Private Placement&#148;) of 9,118,184 Common Shares and 3,381,816 fully-funded, <FONT STYLE="white-space:nowrap">non-voting</FONT> subscription receipts, exchangeable into Common Shares on a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">one-for-one</FONT></FONT> basis (the &#147;Exchangeable Subscription Receipts&#148;) in lieu of Common Shares, in each case, at the Offering Price, for US$12,500,000 aggregate gross proceeds, less a capital commitment fee
of 1.5% payable to Investissement Qu&eacute;bec and Investissement Qu&eacute;bec&#146;s legal fees. The component of the Concurrent Private Placement in the form of Exchangeable Subscription Receipts is designed to ensure that, following completion
of the Public Offering and the Concurrent Private Placement, Investissement Qu&eacute;bec does not have beneficial ownership or control over more than 19.9% of the issued and outstanding Common Shares and therefore is not a &#147;control
person&#148; within applicable Canadian securities laws. All securities issued in connection with the Concurrent Private Placement are subject to a four-month hold period from the closing date under applicable Canadian securities laws, in addition
to such other restrictions as may apply under applicable securities laws of jurisdictions outside Canada. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company also entered into an investor
rights agreement, pursuant to which Investissement Qu&eacute;bec will be entitled to nominate one director to the Company&#146;s board of directors for as long as it holds 50% of the Common Shares purchased pursuant to the Concurrent Private
Placement. Copies of the subscription agreement, the exchangeable receipt agreement setting forth the terms and conditions of the Exchangeable Subscription Receipts and the investor rights agreement, when available, will be filed on SEDAR+ at
<U>www.sedarplus.ca</U>. Summaries of the subscription agreement and the exchangeable receipt agreement and a copy of the investor rights agreement, when available, will be filed on EDGAR at <U>www.sec.gov</U>. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As at the date of closing, Investissement Qu&eacute;bec beneficially owns approximately 19.9% (25.4% if the
Exchangeable Subscription Receipts were to be exchanged into Common Shares) of the issued and outstanding Common Shares. If the Option is exercised in full, Investissement Qu&eacute;bec will beneficially own approximately 19.1% (24.5% if the
Exchangeable Subscription Receipts were to be exchanged into Common Shares) of the issued and outstanding Common Shares as of the date of closing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
Public Offering and the Concurrent Private Placement are subject to final acceptance of the Toronto Stock Exchange. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No securities regulatory authority
has either approved or disapproved the contents of this news release. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any province, state or
jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such province, state or jurisdiction. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Theratechnologies </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Theratechnologies (Nasdaq: THTX)
(TSX: TH) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Further information about Theratechnologies is available on the Company&#146;s website at
<U>www.theratech.com</U>, on SEDAR+ at <U>www.sedarplus.ca</U> and on EDGAR at <U>www.sec.gov</U>. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains forward-looking statements and forward-looking information (collectively, the &#147;Forward-Looking Statements&#148;) within the
meaning of applicable securities laws, that are based on management&#146;s beliefs and assumptions and on information currently available to it. You can identify forward-looking statements by terms such as &#147;may&#148;, &#147;will&#148;,
&#147;should&#148;, &#147;could&#148;, &#147;promising&#148;, &#147;would&#148;, &#147;outlook&#148;, &#147;believe&#148;, &#147;plan&#148;, &#147;envisage&#148;, &#147;anticipate&#148;, &#147;expect&#148; and &#147;estimate&#148;, or the negatives
of these terms, or variations of them. The Forward-Looking Statements contained in this press release include, but are not limited to, statements regarding the exercise of the Option. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although the Forward-Looking Statements contained in this press release are based upon what the Company believes are reasonable assumptions in light of the
information currently available, investors are cautioned against placing undue reliance on these statements since actual results may vary from the Forward-Looking Statements. Forward-Looking Statements assumptions are subject to a number of risks
and uncertainties, many of which are beyond the Company&#146;s control, that could cause actual results to differ materially from those that are disclosed in or implied by such Forward-Looking Statements. These, as well as other, risks and
uncertainties are described more fully in the section titled &#147;Risk Factors&#148; of the preliminary Prospectus Supplement and of the Base Shelf Prospectus in connection with the Public Offering as well as other public filings made by the
Company available on SEDAR+ at <U>www.sedarplus.ca</U> and on EDGAR at <U>www.sec.gov</U>. The reader is cautioned to consider these and other risks and uncertainties carefully and not to put undue reliance on Forward-Looking Statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Forward-Looking Statements reflect current expectations regarding future events and speak only as of the
date of this press release and represent the Company&#146;s expectations as of that date. The Company undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events
or circumstances or otherwise, except as may be required by applicable law. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contacts: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investor inquiries: </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Philippe Dubuc </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Senior Vice President and Chief Financial Officer </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>pdubuc@theratech.com </U></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-438-315-6608</FONT></FONT></FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Media inquiries: </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Julie Schneiderman </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Senior Director, Communications&nbsp;&amp;
Corporate Affairs </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>communications@theratech.com </U></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-514-336-7800</FONT></FONT></FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g559945g1031190144799.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g559945g1031190144799.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !$ *,# 2(  A$! Q$!_\0
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M>'M8\-WFFV4=Q=SW";(PT)55/9N>XZ\5N_"W2+W2?";"^B>%[F=IDB<895(
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
#?__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
